Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04666441 · ClinicalTrials.gov registry record · Phase 2
COVID-19 Study Assessing the Virologic Efficacy of REGN10933+REGN10987 Across Different Dose Regimens in Adult Outpatients With SARS-CoV-2 Infection
A Phase 2 study, sponsored by Regeneron Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 1,149
- Enrollment target
NCT04666441 is a Phase 2 study that has completed, run by Regeneron Pharmaceuticals. The registered enrollment target is 1,149 participants.
The verdict
NCT04666441, a Phase 2 study, has completed, sponsored by Regeneron Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 1,149 participants
- Enrollment target
Study Summary
The primary objective of the study is to assess the virologic efficacy of REGN10933+REGN10987 across different intravenous and subcutaneous doses compared to placebo. The secondary objectives of the study are: * To evaluate additional indicators of virologic efficacy of REGN10933+REGN10987 compared to placebo * To evaluate the safety and tolerability of REGN10933+REGN10987 compared to placebo * To assess the concentrations of REGN10933 and REGN10987 in serum over time * To assess the immunogenicity of REGN10933 and REGN10987
Interventions
- DRUG Placebo
- DRUG REGN10933+REGN10987 combination therapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,149 participants |
| Start Date | 2020-12-15 |
| Est. Completion | 2021-09-21 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04666441
The ClinicalTrials.gov registry entry for NCT04666441 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 1,149 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Regeneron Pharmaceuticals, which has 280 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04666441 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04666441 about?
NCT04666441 is a clinical study titled "COVID-19 Study Assessing the Virologic Efficacy of REGN10933+REGN10987 Across Different Dose Regimens in Adult Outpatients With SARS-CoV-2 Infection". The primary objective of the study is to assess the virologic efficacy of REGN10933+REGN10987 across different intravenous and subcutaneous doses compared to placebo. The secondary objectives of the study are: * To evaluate additional indicators of virologic efficacy of REGN10933+REGN10987 compare...
What is the current status of trial NCT04666441?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 1,149 participants. The study started on 2020-12-15. Estimated completion is 2021-09-21.
What interventions are being tested in trial NCT04666441?
The interventions under investigation include: Placebo (DRUG), REGN10933+REGN10987 combination therapy (DRUG).
Who is sponsoring clinical trial NCT04666441?
This trial is sponsored by Regeneron Pharmaceuticals, which has 280 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.